AA
PTCT icon

AlphaCentric Advisors’s PTC Therapeutics PTCT Stock Holding History

AlphaCentric Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$697K Buy
17,500
+5,000
+40% +$191K 0.2% 50
2021
Q3 		$465K Buy
12,500
+2,500
+25% +$103K 0.12% 75
2021
Q2 		$423K Buy
+10,000
New +$428K 0.11% 70

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AlphaCentric Advisors's PTCT Position: Q4 2021 in Review

AlphaCentric Advisors increased its PTC Therapeutics (PTCT) stake by 40% in Q4 2021, buying an estimated $191K and bringing the position to 17,500 shares worth $697K. The position accounts for 0.2% of the portfolio, ranked #50.

AlphaCentric Advisors first reported a position in PTCT in Q2 2021 and has held it in 3 quarters since. 178 funds tracked by Wall St. Rank hold PTCT as of Q4 2021.

  • AlphaCentric Advisors held 17,500 shares of PTC Therapeutics worth $697K as of Q4 2021.
  • AlphaCentric Advisors bought 5,000 PTC Therapeutics shares in Q4 2021, an estimated $191K.
  • PTC Therapeutics made up 0.2% of AlphaCentric Advisors's portfolio in Q4 2021, its #50 holding.
  • AlphaCentric Advisors first reported a position in PTC Therapeutics in Q2 2021 and has held it in 3 quarters since.
  • 178 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.